Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Successful closure of US FDA Inspection at Piramal Pharma s manufacturing facility located at Digwal, Telangana, India
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Piramal Pharma has received an Establishment Inspection Report (EIR) from the US FDA for its manufacturing facility in Digwal, Telangana, marking successful closure of the inspection that began in February 2026. The FDA has officially closed the inspection without issuing any adverse findings. This is a positive regulatory development as the facility maintains its compliance status to serve the US pharmaceutical market. The company disclosed this on the first working day after receiving the EIR on 18th May 2026.
Positive for shareholders - the successful FDA inspection closure removes regulatory uncertainty, ensures uninterrupted US market access, and validates the facility's quality standards. This supports revenue from US exports and eliminates risk of production disruption.